NG2 Antibody - #DF12589

(4)   (9)  
Product: NG2 Antibody
Catalog: DF12589
Description: Rabbit polyclonal antibody to NG2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit
Mol.Wt.: 251 kDa，320kDa; 251kD(Calculated).
Uniprot: Q6UVK1
RRID: AB_2845551

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(83%)
Clonality:
Polyclonal
Specificity:
NG2 Antibody detects endogenous levels of total NG2.
RRID:
AB_2845551
Cite Format: Affinity Biosciences Cat# DF12589, RRID:AB_2845551.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

4732461B14Rik; AN2; AN2 proteoglycan; Chondroitin sulfate proteoglycan 4 (melanoma-associated); Chondroitin sulfate proteoglycan 4; Chondroitin sulfate proteoglycan NG2; Cspg4; Cspg4 chondroitin sulfate proteoglycan 4; CSPG4_HUMAN; HMW-MAA; HSN tumor-specific antigen; Kiaa4232; MCSP; MCSPG; MEL-CSPG; Melanoma chondroitin sulfate proteoglycan; Melanoma-associated chondroitin sulfate proteoglycan; MELCSPG; MSK16; NG2;

Immunogens

Immunogen:
Uniprot:

Q6UVK1(CSPG4_HUMAN) >>Visit HPA database.

Gene(ID):
CSPG4(1464)
Expression:
Q6UVK1 CSPG4_HUMAN:

Detected only in malignant melanoma cells.

Sequence:
MQSGPRPPLPAPGLALALTLTMLARLASAASFFGENHLEVPVATALTDIDLQLQFSTSQPEALLLLAAGPADHLLLQLYSGRLQVRLVLGQEELRLQTPAETLLSDSIPHTVVLTVVEGWATLSVDGFLNASSAVPGAPLEVPYGLFVGGTGTLGLPYLRGTSRPLRGCLHAATLNGRSLLRPLTPDVHEGCAEEFSASDDVALGFSGPHSLAAFPAWGTQDEGTLEFTLTTQSRQAPLAFQAGGRRGDFIYVDIFEGHLRAVVEKGQGTVLLHNSVPVADGQPHEVSVHINAHRLEISVDQYPTHTSNRGVLSYLEPRGSLLLGGLDAEASRHLQEHRLGLTPEATNASLLGCMEDLSVNGQRRGLREALLTRNMAAGCRLEEEEYEDDAYGHYEAFSTLAPEAWPAMELPEPCVPEPGLPPVFANFTQLLTISPLVVAEGGTAWLEWRHVQPTLDLMEAELRKSQVLFSVTRGARHGELELDIPGAQARKMFTLLDVVNRKARFIHDGSEDTSDQLVLEVSVTARVPMPSCLRRGQTYLLPIQVNPVNDPPHIIFPHGSLMVILEHTQKPLGPEVFQAYDPDSACEGLTFQVLGTSSGLPVERRDQPGEPATEFSCRELEAGSLVYVHRGGPAQDLTFRVSDGLQASPPATLKVVAIRPAIQIHRSTGLRLAQGSAMPILPANLSVETNAVGQDVSVLFRVTGALQFGELQKQGAGGVEGAEWWATQAFHQRDVEQGRVRYLSTDPQHHAYDTVENLALEVQVGQEILSNLSFPVTIQRATVWMLRLEPLHTQNTQQETLTTAHLEATLEEAGPSPPTFHYEVVQAPRKGNLQLQGTRLSDGQGFTQDDIQAGRVTYGATARASEAVEDTFRFRVTAPPYFSPLYTFPIHIGGDPDAPVLTNVLLVVPEGGEGVLSADHLFVKSLNSASYLYEVMERPRHGRLAWRGTQDKTTMVTSFTNEDLLRGRLVYQHDDSETTEDDIPFVATRQGESSGDMAWEEVRGVFRVAIQPVNDHAPVQTISRIFHVARGGRRLLTTDDVAFSDADSGFADAQLVLTRKDLLFGSIVAVDEPTRPIYRFTQEDLRKRRVLFVHSGADRGWIQLQVSDGQHQATALLEVQASEPYLRVANGSSLVVPQGGQGTIDTAVLHLDTNLDIRSGDEVHYHVTAGPRWGQLVRAGQPATAFSQQDLLDGAVLYSHNGSLSPRDTMAFSVEAGPVHTDATLQVTIALEGPLAPLKLVRHKKIYVFQGEAAEIRRDQLEAAQEAVPPADIVFSVKSPPSAGYLVMVSRGALADEPPSLDPVQSFSQEAVDTGRVLYLHSRPEAWSDAFSLDVASGLGAPLEGVLVELEVLPAAIPLEAQNFSVPEGGSLTLAPPLLRVSGPYFPTLLGLSLQVLEPPQHGALQKEDGPQARTLSAFSWRMVEEQLIRYVHDGSETLTDSFVLMANASEMDRQSHPVAFTVTVLPVNDQPPILTTNTGLQMWEGATAPIPAEALRSTDGDSGSEDLVYTIEQPSNGRVVLRGAPGTEVRSFTQAQLDGGLVLFSHRGTLDGGFRFRLSDGEHTSPGHFFRVTAQKQVLLSLKGSQTLTVCPGSVQPLSSQTLRASSSAGTDPQLLLYRVVRGPQLGRLFHAQQDSTGEALVNFTQAEVYAGNILYEHEMPPEPFWEAHDTLELQLSSPPARDVAATLAVAVSFEAACPQRPSHLWKNKGLWVPEGQRARITVAALDASNLLASVPSPQRSEHDVLFQVTQFPSRGQLLVSEEPLHAGQPHFLQSQLAAGQLVYAHGGGGTQQDGFHFRAHLQGPAGASVAGPQTSEAFAITVRDVNERPPQPQASVPLRLTRGSRAPISRAQLSVVDPDSAPGEIEYEVQRAPHNGFLSLVGGGLGPVTRFTQADVDSGRLAFVANGSSVAGIFQLSMSDGASPPLPMSLAVDILPSAIEVQLRAPLEVPQALGRSSLSQQQLRVVSDREEPEAAYRLIQGPQYGHLLVGGRPTSAFSQFQIDQGEVVFAFTNFSSSHDHFRVLALARGVNASAVVNVTVRALLHVWAGGPWPQGATLRLDPTVLDAGELANRTGSVPRFRLLEGPRHGRVVRVPRARTEPGGSQLVEQFTQQDLEDGRLGLEVGRPEGRAPGPAGDSLTLELWAQGVPPAVASLDFATEPYNAARPYSVALLSVPEAARTEAGKPESSTPTGEPGPMASSPEPAVAKGGFLSFLEANMFSVIIPMCLVLLLLALILPLLFYLRKRNKTGKHDVQVLTAKPRNGLAGDTETFRKVEPGQAIPLTAVPGQGPPPGGQPDPELLQFCRTPNPALKNGQYWV

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Rabbit
83
Zebrafish
29
Dog
0
Xenopus
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q6UVK1 As Substrate

Site PTM Type Enzyme
T21 Phosphorylation
S163 Phosphorylation
S643 Phosphorylation
Y743 Phosphorylation
T1591 Phosphorylation
S2036 Phosphorylation
T2042 Phosphorylation
N2075 N-Glycosylation
T2077 Phosphorylation
S2079 Phosphorylation
T2252 Phosphorylation P17252 (PRKCA)
T2261 Phosphorylation
K2263 Ubiquitination
T2274 Phosphorylation
K2277 Ubiquitination
T2310 Phosphorylation
K2316 Ubiquitination
Y2320 Phosphorylation

Research Backgrounds

Function:

Proteoglycan playing a role in cell proliferation and migration which stimulates endothelial cells motility during microvascular morphogenesis. May also inhibit neurite outgrowth and growth cone collapse during axon regeneration. Cell surface receptor for collagen alpha 2(VI) which may confer cells ability to migrate on that substrate. Binds through its extracellular N-terminus growth factors, extracellular matrix proteases modulating their activity. May regulate MPP16-dependent degradation and invasion of type I collagen participating in melanoma cells invasion properties. May modulate the plasminogen system by enhancing plasminogen activation and inhibiting angiostatin. Functions also as a signal transducing protein by binding through its cytoplasmic C-terminus scaffolding and signaling proteins. May promote retraction fiber formation and cell polarization through Rho GTPase activation. May stimulate alpha-4, beta-1 integrin-mediated adhesion and spreading by recruiting and activating a signaling cascade through CDC42, ACK1 and BCAR1. May activate FAK and ERK1/ERK2 signaling cascades.

PTMs:

O-glycosylated; contains glycosaminoglycan chondroitin sulfate which are required for proper localization and function in stress fiber formation (By similarity). Involved in interaction with MMP16 and ITGA4.

Phosphorylation by PRKCA regulates its subcellular location and function in cell motility.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein>Extracellular side. Apical cell membrane>Single-pass type I membrane protein>Extracellular side. Cell projection>Lamellipodium membrane>Single-pass type I membrane protein>Extracellular side. Cell surface.
Note: Localized at the apical plasma membrane it relocalizes to the lamellipodia of astrocytoma upon phosphorylation by PRKCA. Localizes to the retraction fibers. Localizes to the plasma membrane of oligodendrocytes (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected only in malignant melanoma cells.

Subunit Structure:

Interacts with the first PDZ domain of MPDZ. Interacts with PRKCA. Binds TNC, laminin-1, COL5A1 and COL6A2. Interacts with PLG and angiostatin. Binds FGF2 and PDGFA. Interacts with GRIP1, GRIP2 and GRIA2. Forms a ternary complex with GRIP1 and GRIA2 (By similarity). Interacts with LGALS3 and the integrin composed of ITGB1 and ITGA3. Interacts with ITGA4 through its chondroitin sulfate glycosaminoglycan. Interacts with BCAR1, CDC42 and ACK1. Interacts with MMP16.

References

1). Effects of 17β-trenbolone exposure on sex hormone synthesis and social behaviours in adolescent mice. Chemosphere (PubMed: 31869672) [IF=8.8]

Application: IF/ICC    Species: mice    Sample: medial prefrontal cortex (mPFC)

Fig. 5. Effect of 17ββββ-TBOH on the myelination of the mPFC in adolescent mice. (A) Quantitative 893 real-time PCR (qRT-PCR) of myelin gene transcripts in the mPFC (n=4). (B-C) Confocal images and 894 quantification of MBP+ (green) myelinated fibres in the mPFC. DAPI (blue) was used as a nuclear 895 counterstain (n=12 fields from 3 mice per treatment condition). (D-F) Confocal images and 89， quantification of NG2+ (green) cells and CC1+ (red) cells in the mPFC. DAPI (blue) was used as a 897 nuclear counterstain (n=12 fields from 3 mice per treatment condition). Scale bar=60 µm. *p<0.05 **P 898 < 0.01, ***P < 0.001, and ****P < 0.0001 by one-way ANOVA followed by Tukey’s post hoc test. 899 Data are presented as means ± SEM.
2). EAAT3 impedes oligodendrocyte remyelination in chronic cerebral hypoperfusion-induced white matter injury. CNS neuroscience & therapeutics (PubMed: 37803915) [IF=5.5]

Application: WB    Species: Mouse    Sample:

FIGURE 3 PDC administration increases the survival, proliferation, and migration of OPCs. (A, B) Representative immunoblotting and quantification showed the expression of NG2 in white matter on Day 14 after BCAS and the expression can increase after injection of PDC. (C) Representative images of NG2 expression in CC in each group. (D) Results of quantitative analysis of the NG2‐positive cells in each field of CC in each group, n = 3, 2 or 3 images per animal. (E) Representative images of NG2 expression in SVZ in each group. (F) Results of immunofluorescent intensity of the NG2‐positive cells in each field of SVZ in each group, n = 3, 2 or 3 images per animal. (G) Representative immunofluorescence co‐staining images of EdU (red) and NG2 (green) in SVZ in each group. (H) Quantitative analysis of % EdU+/ NG2+ cells in total DAPI of SVZ, n = 3, 2 or 3 images per animal. (I) Representative immunofluorescence images of EdU immunoreactive primary OPCs in the indicated groups. (J) % EdU‐positive OPCs in total DAPI in the indicated groups, n = 3–5 images from at least three independent experiments. (K) Representative photomicrographs of migrated OPCs. (L) Quantitative analysis of the numbers of migrated OPCs, n = 3–5 images from at least three independent experiments. There was no difference in body weight between mice in each group. The data for each group conformed to a normal distribution. p Value was determined by ANOVA with Bonferroni's post‐hoc test. The data of H were analyzed using the Mann–Whitney U test. *p 

Application: IF/ICC    Species: Mouse    Sample:

FIGURE 3 PDC administration increases the survival, proliferation, and migration of OPCs. (A, B) Representative immunoblotting and quantification showed the expression of NG2 in white matter on Day 14 after BCAS and the expression can increase after injection of PDC. (C) Representative images of NG2 expression in CC in each group. (D) Results of quantitative analysis of the NG2‐positive cells in each field of CC in each group, n = 3, 2 or 3 images per animal. (E) Representative images of NG2 expression in SVZ in each group. (F) Results of immunofluorescent intensity of the NG2‐positive cells in each field of SVZ in each group, n = 3, 2 or 3 images per animal. (G) Representative immunofluorescence co‐staining images of EdU (red) and NG2 (green) in SVZ in each group. (H) Quantitative analysis of % EdU+/ NG2+ cells in total DAPI of SVZ, n = 3, 2 or 3 images per animal. (I) Representative immunofluorescence images of EdU immunoreactive primary OPCs in the indicated groups. (J) % EdU‐positive OPCs in total DAPI in the indicated groups, n = 3–5 images from at least three independent experiments. (K) Representative photomicrographs of migrated OPCs. (L) Quantitative analysis of the numbers of migrated OPCs, n = 3–5 images from at least three independent experiments. There was no difference in body weight between mice in each group. The data for each group conformed to a normal distribution. p Value was determined by ANOVA with Bonferroni's post‐hoc test. The data of H were analyzed using the Mann–Whitney U test. *p 
3). GDF11 protects against glucotoxicity-induced mice retinal microvascular endothelial cell dysfunction and diabetic retinopathy disease. MOLECULAR AND CELLULAR ENDOCRINOLOGY (PubMed: 34391845) [IF=4.1]

Application: IF/ICC    Species: Mice    Sample: retinas

Fig. 2. GDF11 restoration decreases cell death in the retinas of diabetic mice. Five adjacent retinal sections were obtained from an eye of each diabetic mouse (n = 3 mice from each group). (A) Representative images of the retinal sections stained for TUNEL assay. The nuclei were stained with DAPI (blue). The white arrows indicate apoptotic cells (red). Scale bar, 20 μm. (B) Quantification of the TUNEL(+) cells. Results are shown as the mean ± SD number of TUNEL(+) cells/mm2 . *, P < 0.05 vs. Vehicle group; #, P < 0.05 vs. AAV-GFP group. (C) Representative images of retinal sections double-stained for anti-NG2 (pericytes, green) and anti-CD31 (endothelial cells, red). The nuclei were stained with DAPI (blue). Scale bar, 20 μm. (D and E) Quantification of the NG2-immunopositive (+) vascular area (D) and the CD31-immunopositive (+) vascular area (E). Results are expressed as mean ± SD of NG2 (+) or CD31(+) vascular area/mm2 . *, P < 0.05 vs. Vehicle group; #, P < 0.05 vs. AAV-GFP group.
4). Calycosin-7-O-β-D-Glucoside Treatment Promotes Axonal Regeneration via Rho/ROCK Pathway After Ischemia/Reperfusion Injury. Research Square

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.